AbbVie receives US regulatory approval for Mavyret

AbbVie has received the US Food and Drug Administration (FDA) approval for Mavyret (glecaprevir / pibrentasvir) to lower the therapy period from 12 to eight weeks in hepatitis C (HCV) patients with cirrhosis. The indication for once-daily therapy is meant for treatment-naïve, compensated cirrhotic, chronic HCV patients across all genotypes (GT1-6). Previously, the drug secured FDA approval in August 2017 for eight-week, pan-genotypic therapy for treatment-naïve HCV patients without cirrhosis. Mavyret is a ribavirin-free medication that consists of 100mg glecaprevir in combination with 40mg pibrentasvir. Glecaprevir is an NS3 / 4A protease inhibitor, while pibrentasvir inhibits NS5A. AbbVie discovered glecaprevir as part of its ongoing alliance with Enanta Pharmaceuticals, which focuses on HCV protease inhibitors and regimens, including protease inhibitors.

Spotlight

Spotlight

Related News